Kura Oncology Reports Promising Early Results for Darlifarnib in Combination Cancer Therapy
Reuters
Oct 18, 2025
<a href="https://laohu8.com/S/KURA">Kura Oncology</a> Reports Promising Early Results for Darlifarnib in Combination Cancer Therapy
Kura Oncology Inc., a clinical-stage biopharmaceutical company, announced new preliminary data from its farnesyl transferase inhibitor $(FTI)$ programs-darlifarnib (KO-2806) and tipifarnib-at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Germany, held from October 17 to 21, 2025. The results, which have already been presented, include early clinical and preclinical findings supporting darlifarnib's potential to enhance the clinical benefit of PI3Kα inhibitors, KRAS inhibitors, and tyrosine kinase inhibitors. In an ongoing dose-escalation clinical trial, the combination of darlifarnib and cabozantinib in renal cell carcinoma $(RCC)$ demonstrated a 50% objective response rate and an 80% disease control rate. Additional data from the FIT-001 Phase 1 trial indicate a manageable safety and tolerability profile for darlifarnib monotherapy in advanced solid tumors at doses from 3 to 10 mg per day.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9547938-en) on October 18, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.